Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KPTI
Strong SellSinkerKaryopharm Therapeutics Inc. · Healthcare · United States · $168M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to developing and commercializing novel cancer therapies, primarily focusing on its proprietary nuclear export inhibitors, with XPOVIO as its lead approved product. The company's competitive moat lies in its unique drug class and intellectual property in nuclear export modulation, addressing significant unmet needs in oncology. Karyopharm operates as an innovative biotech, expanding the indications for its approved drug and advancing its pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.1M | 146.0M | 145.2M | 146.1M | -2.4% | 146.6M | 135.6M | 173.6M | 9.0% |
| EPS | -10.09 | -6.35 | -3.51 | -17.93 | — | -14.33 | — | — | — |
| Shares | 22.7M | 22.7M | 22.7M | 18.3M | -19.2% | 22.7M | — | — | — |
| Debt | 179.1M | 177.0M | 194.5M | 233.6M | 9.3% | 328.5M | — | — | — |
| Equity | -16.7M | -136.2M | -186.0M | -292.9M | — | — | — | — | — |
| Op CF | -149.6M | -92.7M | -127.5M | -75.4M | — | -65.3M | — | — | — |
| Inv CF | -104.3M | 7.9M | 95.5M | 43.4M | — | — | — | — | — |
| Fin CF | 193.7M | 1.1M | 41.6M | 30.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KPTI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc.(you) | $168M | 11 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 10 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 11 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| CNTN | Canton Strategic Holdings, Inc. | $177M | 9 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%